Dementia has no cure, which makes prevention one of the few real levers available — and a large trial in rural China just added some of the strongest evidence yet that a genuinely low-tech intervention can move the needle. Bringing blood pressure under tighter control, using local community health workers instead of physicians, reduced dementia risk by 15% over seven years.
Key Takeaways
- The China Rural Hypertension Control Program (CRHCP) followed 33,995 adults over 40 with uncontrolled hypertension across 326 rural villages, half receiving an intensive blood-pressure intervention and half receiving usual care.
- The intervention was delivered by trained non-physician community health workers, not doctors, who adjusted medications using a simple protocol and provided lifestyle coaching, with physician supervision.
- After 7 years, the intervention group had a 15% lower risk of all-cause dementia than the usual-care group, extending findings the same trial first reported after 4 years of follow-up.
- The intervention group also achieved a substantially larger blood pressure reduction (22 mmHg systolic, 9.3 mmHg diastolic more than usual care) and had fewer serious adverse events overall, not more.
How the Trial Was Designed
Led by Professor Yingxian Sun of China Medical University and Professor Jiang He of UT Southwestern Medical Center, the trial randomized 326 villages, evenly split, to either the intervention or usual care. In intervention villages, trained non-physician community healthcare providers — not doctors — initiated and adjusted blood pressure medications using a straightforward, stepped protocol, aiming for a target below 130/80 mmHg, while also coaching participants on lifestyle changes and medication adherence; primary care physicians supervised the program but weren’t the ones managing day-to-day patient care. Usual-care villages continued standard hypertension management through China’s existing rural health insurance system. All participants were 40 or older with uncontrolled hypertension at the study’s start.
What the Results Showed
The trial’s initial results, published in Nature Medicine in April 2025, found that after 4 years, the intervention group’s systolic blood pressure had dropped 22 mmHg more, and diastolic pressure 9.3 mmHg more, than the usual-care group — a substantial gap. That earlier analysis also found a 16% reduction in combined all-cause dementia and mild cognitive impairment, and notably, serious adverse events were less common in the intervention group, not more, addressing a natural worry that more aggressive blood pressure treatment might cause its own problems in older adults.
The new data, presented by Dr. Shanshan Zhong at the European Society of Cardiology Congress in Munich on August 30, extends the follow-up to 7 years and reports a 15% reduction specifically in all-cause dementia — confirming the earlier signal held up, and didn’t fade, with several more years of follow-up. “These results support the long-term sustainability of integrating strategies for blood pressure control… into routine primary care,” Sun said.
Why the Delivery Model Matters as Much as the Result
Professor Sun was direct about the significance of who delivered the intervention: “In this large community-based trial, a scalable, non-physician-led intervention… not only resulted in substantial reductions in blood pressure but also reduced the risk of dementia.” That’s a meaningful detail beyond the dementia statistic itself — much of the world, including many rural and lower-resource areas, has far more community health workers than specialist physicians available. A model that works when delivered by trained non-physicians, rather than requiring specialist medical care, is inherently easier to scale to places that need it most.
This Isn’t an Isolated Finding
This result lines up with earlier research using a different design and population: the US-based SPRINT-MIND trial, involving more than 9,000 participants, found intensive blood pressure control produced a statistically significant 19% reduction in new cases of mild cognitive impairment, along with a trend toward less dementia that didn’t quite reach statistical significance on its own. Having a large trial in a different country, health system, and population arrive at a similar conclusion strengthens confidence that this is a real, generalizable effect rather than a pattern specific to one study population.
What This Means for You
Dementia cases are projected to nearly triple globally, from 57 million in 2019 to a projected 153 million by 2050, making effective, scalable prevention strategies a genuine public health priority rather than a marginal concern. This trial adds strong, randomized evidence that treating hypertension aggressively — not just adequately — may meaningfully lower dementia risk, on top of its already well-established cardiovascular benefits. If you or a family member has hypertension, particularly if it’s not well controlled, this is a good reason to talk to your doctor about your specific blood pressure targets, rather than assuming any treatment is equally protective.
Sources: He, J., Sun, Y., et al. (2025). Blood pressure reduction and all-cause dementia in people with uncontrolled hypertension: an open-label, blinded-endpoint, cluster-randomized trial. Nature Medicine; Zhong, S., Sun, Y., et al. (2026). Seven-year follow-up data presented at the European Society of Cardiology Congress, Munich, Aug. 30, 2026; European Society of Cardiology, press release, “Long-term intensive blood-pressure control reduces dementia risk.”